dc.contributor.author | Kavanaugh, A | |
dc.contributor.author | Marzo-Ortega, H | |
dc.contributor.author | Vender, R | |
dc.contributor.author | Wei, C-C | |
dc.contributor.author | Birt, J | |
dc.contributor.author | Adams, DH | |
dc.contributor.author | Benichou, O | |
dc.contributor.author | Lin, C-Y | |
dc.contributor.author | Nash, P | |
dc.date.accessioned | 2020-08-24T00:37:09Z | |
dc.date.available | 2020-08-24T00:37:09Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0392-856X | |
dc.identifier.uri | http://hdl.handle.net/10072/396665 | |
dc.description.abstract | Objectives: To report patient-reported outcomes (PROs) of ixekizumab-treated patients with psoriatic arthritis (PsA) and an inadequate response (IR) or intolerance to tumour necrosis factor inhibitors (TNFi) to 52 weeks.
Methods: In SPIRIT-P2, patients with active PsA and an IR or intolerance to TNFi were randomised to ixekizumab 80 mg every 4 weeks (IXEQ4W; N=122) or every 2 weeks (IXEQ2W; N=123), or placebo (PBO; N=118) during the initial 24-week double-blind treatment period. At Week 16, background therapy was modified for IRs; additionally, IRs in the placebo group were re-randomised (1:1) to IXEQ2W or IXEQ4W. Patients receiving ixekizumab at Week 24 received the same dose during the study remainder. Patients completed several PROs for PsA disease activity, skin, health-related quality of life (HRQOL, and work through Week 52.
Results: Ixekizumab-treated patients reported significant improvements versus PBO in 36-Item Short Form Health Survey version 2, European Quality of Life 5 Dimensions visual analogue scale, Bath Ankylosing Spondylitis Disease Activity Index (total score and question 2), and Work Productivity and Activity Impairment Questionnaire-Specific Health Problem (3 of 4 domains) through Week 24. At Week 24, 9% (PBO), 52% (IXEQ4W), and 50% (IXEQ2W) of patients reported Dermatology Life Quality Index scores of 0 or 1; 0% (PBO) and 24% (IXEQ4W and IXEQ2W) reported Itch Numeric Rating Scale score of 0. Where data were collected, improvements persisted through Week 52.
Conclusions: In patients with PsA and an IR or intolerance to TNFi, ixekizumab significantly improved disease activity, skin symptoms, HRQOL, and work productivity to 52 weeks. | |
dc.description.peerreviewed | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Clinical and Experimental Rheumatology | |
dc.publisher.uri | https://www.clinexprheumatol.org/abstract.asp?a=12947 | |
dc.relation.ispartofpagefrom | 566 | |
dc.relation.ispartofpageto | 574 | |
dc.relation.ispartofissue | 4 | |
dc.relation.ispartofjournal | Clinical and Experimental Rheumatology | |
dc.relation.ispartofvolume | 37 | |
dc.subject.fieldofresearch | Clinical sciences | |
dc.subject.fieldofresearchcode | 3202 | |
dc.subject.keywords | Science & Technology | |
dc.subject.keywords | Life Sciences & Biomedicine | |
dc.subject.keywords | Rheumatology | |
dc.subject.keywords | ixekizumab | |
dc.subject.keywords | quality of life | |
dc.title | Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | Kavanaugh, A; Marzo-Ortega, H; Vender, R; Wei, C-C; Birt, J; Adams, DH; Benichou, O; Lin, C-Y; Nash, P, Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks, Clinical and Experimental Rheumatology, 2019, 37 (4), pp. 566-574 | |
dcterms.dateAccepted | 2018-08-27 | |
dc.date.updated | 2020-08-24T00:34:19Z | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Nash, Peter | |